Enhancement of SARS-CoV-2 infection and growth by an ACE2-specific
monoclonal antibody
- Guangxiang Luo
Abstract
SARS-CoV-2 causes COVID-19 pandemic and continues to pose a threat to
global public health through genetic mutation. In this study, we have
found that an ACE2-specific monoclonal antibody at low concentration was
able to greatly enhance SARS-CoV-2 infection and growth in cell culture.
Strikingly, it promotes SARS-CoV-2 plaque formation, resulting in
accurate titration of different SARS-CoV-2 variants, particularly the
newly emerged Omicron variants, which otherwise cannot be determined by
standard plaque assays. Quantification of infectious titers of the newly
emerged variants will facilitate the development and evaluation of
vaccines and antiviral drugs against SARS-CoV-2.23 Feb 2023Submitted to Journal of Medical Virology 23 Feb 2023Submission Checks Completed
23 Feb 2023Assigned to Editor
23 Feb 2023Review(s) Completed, Editorial Evaluation Pending
23 Feb 2023Reviewer(s) Assigned
24 Feb 2023Editorial Decision: Revise Minor
10 Mar 20231st Revision Received
15 Mar 2023Submission Checks Completed
15 Mar 2023Assigned to Editor
15 Mar 2023Review(s) Completed, Editorial Evaluation Pending
16 Mar 2023Editorial Decision: Accept